Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESS

• E. Arriola ^[1] ; A. Paredes-Lario ^[2] ; R. García-Gomez ^[3] ; P. Diz-Tain ^[6] ; M. Constenla ^[7] ; C. García-Girón ^[4] ; G. Márquez ^[8] ; M. Reck ^[9] ; G. López-Vivanco ^[5]
  1. [1] Hospital del Mar

     Hospital del Mar

     Barcelona, España

     
  2. [2] Hospital Universitario de Donostia

     Hospital Universitario de Donostia

     San Sebastián, España

     
  3. [3] Hospital General Universitario Gregorio Marañón

     Hospital General Universitario Gregorio Marañón

     Madrid, España

     
  4. [4] Complejo Asistencial Universitario de Burgos

     Complejo Asistencial Universitario de Burgos

     Burgos, España

     
  5. [5] Instituto de Investigación Sanitaria Biocruces Bizkaia

     Instituto de Investigación Sanitaria Biocruces Bizkaia

     Barakaldo, España

     
  6. [6] Complejo Asistencial Universitario de León, España
  7. [7] Complexo Hospitalario de Pontevedra, España
  8. [8] AstraZeneca Madrid, España
  9. [9] German Centre for Lung Research, Alemania

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 20, Nº. 10 (October 2018), 2018, págs. 1261-1267
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Purpose The analysis of epidermal growth factor receptor (EGFR) mutations in many patients with advanced non-small-cell lung cancer (aNSCLC) has provided the opportunity for successful treatment with specific, targeted EGFR tyrosine kinase inhibitors. However, this therapeutic decision may be challenging when insufficient tumor tissue is available for EGFR mutation testing. Therefore, blood surrogate samples for EGFR mutation analysis have been suggested.

    Methods Data were collected from the Spanish cohort of patients in the large, non-interventional, diagnostic ASSESS study (NCT01785888) evaluating the utility of circulating free tumor-derived DNA from plasma for EGFR mutation testing. The incidence of EGFR mutation in Spain and the level of concordance between matched tissue/cytology and plasma samples were evaluated.

    Results In a cohort of 154 eligible patients, EGFR mutations were identified in 15.1 and 11.0% of tumor and plasma samples, respectively. The most commonly used EGFR mutation testing method for the tumor tissue samples was the QIAGEN Therascreen® EGFR RGQ PCR kit (52.1%). Fragment Length Analysis + PNA LNA Clamp was used for the plasma samples. The concordance rate for EGFR mutation status between the tissue/cytology and plasma samples was 88.8%; the sensitivity was 45.5%, and the specificity was 96.7%.

    Conclusions The high concordance between the different DNA sources for EGFR mutation testing supports the use of plasma samples when tumor tissue is unavailable.